CSBR - Company ID 0000771856
The table below shows CHAMPIONS ONCOLOGY, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $16.56M | $15.04M | $13.99M | $17.04M | $13.49M | $14.06M |
| Cost of revenue | $8.83M | $7.26M | $8.00M | $6.62M | $7.43M | $7.07M |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.27M | $2.62M | $2.08M | $1.72M | $1.69M | $1.45M |
CHAMPIONS ONCOLOGY, INC. reported annual revenue of $56.94M for fiscal year 2025. That is up 13.5% from $50.16M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $20.24M (FY 2018) to $56.94M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.98M |
| $2.97M |
| $2.57M |
| $2.40M |
| $1.89M |
| $2.53M |
| Operating income | -$276.00K | $185.00K | -$527.00K | $4.50M | $732.00K | $1.33M |
| Income tax | $42.00K | $18.00K | $14.00K | $23.00K | $11.00K | $21.00K |
| Net income | -$279.00K | $268.00K | -$436.00K | $4.50M | $728.00K | $1.31M |
| EPS (diluted) | -$0.02 | $0.02 | -$0.03 | $0.31 | $0.05 | $0.09 |